Acorda Therapeutics Faces Major Setback With 59% Plunge Due to Chapter 11 Bankruptcy Filing
Tuesday, 2 April 2024, 02:00
Acorda Therapeutics Faces Financial Crisis
Acorda Therapeutics is in turmoil after announcing a Chapter 11 bankruptcy filing, resulting in a dramatic 59% stock price decrease. The company attributes its decision to debts amounting to $266.2M, reflecting a challenging financial landscape.
Key Points:
- 59% Plunge: Acorda's stock price plummeted drastically after the bankruptcy filing.
- Debt Struggles: The company's $266.2M debts have intensified its financial woes.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.